{
    "clinical_study": {
        "@rank": "45134", 
        "arm_group": [
            {
                "arm_group_label": "ARN-509", 
                "arm_group_type": "Active Comparator", 
                "description": "ARN-509 Softgel Capsules, 240 mg/day administered orally"
            }, 
            {
                "arm_group_label": "LHRH agonist + ARN-509", 
                "arm_group_type": "Active Comparator", 
                "description": "Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard\u00ae, Zoladex\u00ae, Lupron Depot\u00ae, Trelstar\u00ae) and ARN-509 Softgel Capsules, 240 mg/day administered orally"
            }, 
            {
                "arm_group_label": "LHRH agonist", 
                "arm_group_type": "Active Comparator", 
                "description": "Choice of LHRHa per investigator discretion/site practice guidelines (e.g., Eligard\u00ae, Zoladex\u00ae, Lupron Depot\u00ae, Trelstar\u00ae)."
            }
        ], 
        "brief_summary": {
            "textblock": "The proposed clinical trial will study the effects of 12 months of therapy with ARN-509\n      alone, or in combination with an LHRH agonist (LHRHa), each compared to LHRHa alone, in men\n      with a rapidly rising serum PSA after prior definitive local therapy for prostate cancer.\n      The endpoints selected reflect measurable short term effects of androgen deprivation therapy\n      (ADT), including quality of life and several metabolic parameters.  In addition, the\n      relative effect of each treatment strategy on PSA suppression as well as testosterone\n      recovery (and subsequent PSA progression) after 12 months of therapy will be evaluated."
        }, 
        "brief_title": "The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Histologically proven adenocarcinoma of the prostate\n\n          -  Rising PSA after prior definitive local therapy (radical prostatectomy, external beam\n             radiation, or brachytherapy) or combination of radical prostatectomy and radiotherapy\n             with curative intent\n\n          -  PSA doubling time less than or equal to 12 months\n\n          -  No evidence of metastatic disease by CT/MRI abdomen/pelvis and whole body bone scan\n\n          -  Minimum PSA 1.0 ng/mL if prior radical prostatectomy +/- adjuvant or salvage\n             radiation; nadir + 2.0 ng/mL if prior RT without prior radical prostatectomy\n\n          -  No androgen deprivation therapy or anti-androgen (i.e. bicalutamide) within 12 months\n             of study entry\n\n          -  No prior androgen deprivation therapy (ADT) or anti-androgen for biochemical relapse\n\n          -  Serum testosterone > 150 ng/dL at study entry\n\n          -  No history of seizures or medical conditions which may lower seizure threshold\n\n        Key Exclusion Criteria:\n\n          -  Use of 5-alpha reductase antagonist (i.e. finasteride, dutasteride) within 3 months\n             of study entry\n\n          -  Use of antiandrogen (e.g. flutamide, nilutamide, bicalutamide) within 12 months of\n             study entry\n\n          -  Prior bilateral orchiectomy\n\n          -  Prior hormonal treatment with ADT or antiandrogen for biochemically relapsed prostate\n             cancer\n\n          -  Use of systemic steroids at an equivalent dose of prednisone 5 mg/day or higher at\n             the time of study entry\n\n          -  Any history of seizures or medical condition which lowers seizure threshold"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790126", 
            "org_study_id": "CR103305", 
            "secondary_id": "ARN-509-002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ARN-509", 
                    "LHRH agonist + ARN-509"
                ], 
                "intervention_name": "ARN-509", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LHRH agonist + ARN-509", 
                    "LHRH agonist"
                ], 
                "intervention_name": "LHRH Agonist", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Eligard\u00ae", 
                    "Lupron Depot\u00ae", 
                    "Zoladex\u00ae", 
                    "Trelstar\u00ae"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Androgens", 
                "Hormones", 
                "Triptorelin", 
                "Leuprolide", 
                "Goserelin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer", 
        "lastchanged_date": "May 2, 2014", 
        "link": {
            "description": "To learn how to participate in this trial please click here.", 
            "url": "http://pam.sylogent.com/cr/CR103305"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:"
        }, 
        "overall_official": {
            "affiliation": "Aragon Pharmaceuticals, Inc.", 
            "last_name": "Aragon Pharmaceuticals, Inc Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the mean change in QOL as measured by total FACT-P score after 12 months of therapy with ARN-509 monotherapy and ARN-509 + LHRHa versus LHRHa monotherapy, in men with biochemically relapsed prostate cancer.", 
            "measure": "Mean change in quality of life (QOL) measured by total FACT-P score", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790126"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare ARN-509 monotherapy and ARN-509 + LHRHa vs. LHRHa monotherapy with regards to the mean change in QOL at 24 months as measured by FACT-P, EORTC QLQ-C30/PR-25 and the SHIM scale.", 
                "measure": "Quality of Life Instruments", 
                "safety_issue": "No", 
                "time_frame": "12-24 months"
            }, 
            {
                "description": "To compare ARN-509 monotherapy and ARN-509 + LHRHa vs. LHRHa monotherapy with regards to the proportion of patients who demonstrate testosterone recovery without evidence of PSA or radiographic progression at 24 months, the proportion of patients with a nadir PSA <0.2 ng/mL after 7 months, and the time to PSA progression.", 
                "measure": "PSA Modulation", 
                "safety_issue": "No", 
                "time_frame": "Approx. 7-24 months"
            }, 
            {
                "description": "To compare ARN-509 monotherapy and ARN-509 + LHRHa vs. LHRHa monotherapy with regards to the mean change in baseline in markers of insulin resistance, fasting lipid profile, bone mineral density, serum DHT, and estradiol levels after 12 months, and the time to serum testosterone recovery to >50 ng/dL and >150 ng/dL after cessation of protocol therapy for 12 months.", 
                "measure": "Metabolic and Hormonal Changes", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "To characterize the safety profile of ARN-509 alone and in combinations with a LHRHa based on CTCAE v4.0.", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Aragon Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aragon Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}